Skip to content

BETTERLIFE PHARMA INC.: 10-Q filed 2018-12-18

What BETTERLIFE PHARMA INC. reported in its quarterly report filed 2018-12-18 (fiscal Q3 2019): 31 published measures, 76 facts as tagged in accession 0001477932-18-006051.

This filing

Form
10-Q (quarterly report)
Filed
2018-12-18
Fiscal period
fiscal Q3 2019
Accession
0001477932-18-006051 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BETTERLIFE PHARMA INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-10-317,079,877USD
At 2018-01-31383,817USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-10-313,428,942USD
At 2018-01-31-45,383USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-10-31406,901USD
At 2018-01-3164,511USD
At 2017-10-30250,386USD
At 2017-01-31112,421USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2018-08-01 to 2018-10-31-3,377,521USD92
2018-02-01 to 2018-10-31-6,416,362USD273
2017-08-01 to 2017-10-31530,726USD92
2017-02-01 to 2017-10-30205,362USD272

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2018-02-01 to 2018-10-31-3,560,374USD273
2017-02-01 to 2017-10-30-199,711USD272

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2018-02-01 to 2018-10-314,583,134USD273
2017-02-01 to 2017-10-30332,625USD272

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2018-02-01 to 2018-10-31-659,999USD273

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-10-31-27,135,308USD
At 2018-01-31-20,718,935USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2018-08-01 to 2018-10-3189,623,532shares92
2018-02-01 to 2018-10-3188,079,787shares273
2017-08-01 to 2017-10-3176,761,576shares92
2017-02-01 to 2017-10-3076,055,298shares272

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2018-08-01 to 2018-10-3189,632,532shares92
2018-02-01 to 2018-10-3188,079,787shares273
2017-08-01 to 2017-10-3181,596,692shares92
2017-02-01 to 2017-10-3078,877,344shares272

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2018-08-01 to 2018-10-31-0.04USD/shares92
2018-02-01 to 2018-10-31-0.07USD/shares273
2017-08-01 to 2017-10-310.01USD/shares92
2017-02-01 to 2017-10-300USD/shares272

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2018-08-01 to 2018-10-31-0.04USD/shares92
2018-02-01 to 2018-10-31-0.07USD/shares273
2017-08-01 to 2017-10-310.01USD/shares92
2017-02-01 to 2017-10-300USD/shares272

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-10-313,404USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2018-08-01 to 2018-10-31-1,411,810USD92
2018-02-01 to 2018-10-31-4,039,331USD273
2017-08-01 to 2017-10-31-184,658USD92
2017-02-01 to 2017-10-30-718,931USD272

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-10-31556,024USD
At 2018-01-31149,253USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2018-08-01 to 2018-10-31134,851USD92
2018-02-01 to 2018-10-31299,478USD273
2017-08-01 to 2017-10-317,331USD92
2017-02-01 to 2017-10-3024,481USD272

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-10-313,650,935USD
At 2018-01-31429,200USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2018-10-316,520,449USD
At 2018-01-31234,564USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2018-08-01 to 2018-10-311,411,810USD92
2018-02-01 to 2018-10-314,039,331USD273
2017-08-01 to 2017-10-31184,658USD92
2017-02-01 to 2017-10-30718,931USD272

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2018-10-316,795USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2018-08-01 to 2018-10-3165,029USD92
2018-02-01 to 2018-10-31237,103USD273

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-10-3195,828,235shares
At 2018-01-3182,373,559shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-10-3113,240,333USD
At 2018-01-3111,816,057USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-10-31605,199USD
At 2018-01-31593,728USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-10-315,700USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2018-08-01 to 2018-10-31-3,346,882USD92
2018-02-01 to 2018-10-31-6,404,891USD273
2017-08-01 to 2017-10-31428,224USD92
2017-02-01 to 2017-10-30204,634USD272

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2018-08-01 to 2018-10-31432,112USD92
2018-02-01 to 2018-10-311,609,280USD273
2017-08-01 to 2017-10-3150,480USD92
2017-02-01 to 2017-10-30179,410USD272

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2018-02-01 to 2018-10-31502,080USD273

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2018-02-01 to 2018-10-31269,293USD273

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2017-02-01 to 2017-10-3031,799USD272

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2018-02-01 to 2018-10-31-6,795USD273

Inspect the source

Entity
BETTERLIFE PHARMA INC. / CIK 0001464165
Captured
2026-09-20T09:06:34.124Z
SEC response SHA-256
da89258f023cbc29ad1ecdd31014873fa96a7739fba3e7b66a8b80f8715d36cf

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001464165.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))